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Abstract 26 
Background: Tyrosinemia type 1 is an autosomal recessive disorder of amino acid 27 
metabolism. Without treatment, death in childhood is common. Treatment with nitisinone and 28 
dietary restrictions are associated with improved outcomes; some studies suggest better 29 
outcomes when treatment begins at an asymptomatic stage. Newborn screening allows for 30 
earlier identification, but there is uncertainty regarding the test accuracy of the current 31 
method: succinylacetone measurement in dried blood spots using tandem mass spectrometry.  32 
Methods: We conducted a systematic review of literature published up to January 2016. Two 33 
reviewers independently assessed titles, abstracts, full texts, and conducted quality appraisals. 34 
A single reviewer extracted data, which was checked by a second reviewer.  35 
Results: Ten studies provided test accuracy data: five studies reporting screening experiences 36 
and five case-control studies. Sensitivity (29 cases in total) and specificity (34,403 controls in 37 
total) were 100% in the case-control studies, but could not be calculated in the studies 38 
reporting screening experiences due to a lack of follow-up of screen-negative babies. Positive 39 
predictive values in the screening experience studies ranged from 66.7% (2 true positive 40 
cases, 1 false positive case from ~500,000 people screened) to 100% (8 true positive cases 41 
from 856,671 people screened); negative predictive values could not be calculated. Positive 42 
and negative predictive values cannot be calculated from case-control studies.  43 
Conclusions: Screening for Tyrosinemia type 1 using tandem mass spectrometry 44 
measurement of succinylacetone from dried blood spots appears to be promising. 45 
Confirmation of test accuracy data should be obtained from studies that include a two-year 46 
follow-up of individuals who screen negative. 47 
 48 
Keywords: Systematic review, Tyrosinemia, test accuracy, succinylacetone, inborn errors of 49 
metabolism, newborn blood spot screening, tandem mass spectrometry 50 
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Introduction 51 
Tyrosinemia type 1 (TYR1), also known as fumarylacetoacetase deficiency (Enzyme 52 
Commission Number 3.7.1.2), is an autosomal recessive disorder of amino acid metabolism. 53 
It is caused by a deficiency in the activity of fumarylacetoacetic hydrolase, the final enzyme 54 
in the tyrosine degradation pathway, which leads to a toxic build-up of fumarylacetoacetate, 55 
maleylacetoacetate, and succinylacetone (SUAC) [1].  TYR1 is characterised by progressive 56 
liver, kidney, and neurological disease [2]. Acute (presenting before six months of age), sub-57 
acute (presenting between six and 12 months) and chronic (presenting after one year) forms 58 
of the disease have been described [2]. Without treatment, the prognosis for individuals with 59 
TYR1 is poor, with high levels of death during childhood due to liver failure, recurrent 60 
bleeding, hepatocellular carcinoma, and porphyria-like syndrome with respiratory failure [3].  61 
However, treatment with nitisinone and dietary restrictions are associated with reductions in 62 
morbidity and mortality [4-6]; liver transplantation is indicated if these treatment fail or if 63 
hepatocellular carcinoma develops [2]. The incidence of TYR1 is estimated to be 64 
approximately 1:100,000 live births, but reported values range from 1:1,846 [7] to 1:781,144 65 
live births [8]. The incidence of TYR1 is higher in Quebec, Canada, possibly due to a founder 66 
effect for Tyrosinemia and high gene frequency [7], and in Asian children in the West 67 
Midlands of the UK [9], and in North Africa and the Middle East [10], possibly due to 68 
parental consanguinity [9].  69 
Screening for TYR1 amongst newborn babies is conducted in many countries around the 70 
world. While tyrosine levels have been used as the primary screening marker for TYR1, it is 71 
not consistently raised in individuals who have TYR1 [11], and it can be elevated in 72 
individuals with other conditions and in unaffected babies [12, 13]. In 2004, Allard and 73 
colleagues developed an alternative method to screen for TYR1 using tandem mass 74 
spectrometry (MS/MS) to determine SUAC in dried blood spots (DBS) [14]. A rapid review 75 
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of literature published up to 2012 reported that “Screening programmes using 76 
succinylacetone as a marker have reported 100% sensitivity and 100% specificity. However, 77 
other studies have reported the identification of false positives.” [15]. The aim of the current 78 
review was to examine the range of test accuracy indicators (sensitivity, specificity, and 79 
predictive values) of succinylacetone measurement in DBS using MS/MS for TYR1 80 
screening using full systematic review methods. 81 
 82 
Methods 83 
Search strategy 84 
We conducted searches in the following electronic databases: Medline, Medline In-Process & 85 
Other Non-Indexed Citations, Embase, Web of Science (All Databases), and the Cochrane 86 
Library. We searched using text word and MeSH terms relating to “Tyrosinemia type 1 OR 87 
inborn errors of metabolism”, AND “succinylacetone OR DBS OR (tandem mass 88 
spectrometry AND neonatal screening)”. Full details of the search strategy are provided in 89 
supplement 1. The search was conducted on 26th January 2016. We examined reference lists 90 
of included studies and previous reviews. Experts in the field and organisations were 91 
contacted for studies not in the public domain.  92 
 93 
Eligibility criteria 94 
We included English language journal articles which investigated screening for TYR1 by 95 
MS/MS analysis of SUAC from DBS in newborns. The reference standard was urine testing 96 
for SUAC, clinical detection of TYR1 or two-year follow-up. Outcomes included were any 97 
reported test accuracy measures from cross-sectional studies, case-control studies, or studies 98 
reporting screening experiences. We excluded non-human studies, papers not available in 99 
English, letters, editorials, communications, grey literature, conference abstracts, and studies 100 
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published before 2004 (the year the first paper was published on SUAC measurement in DBS 101 
using MS/MS for TYR1) from our review. 102 
 103 
Screening and data extraction 104 
Screening of titles and abstracts of all retrieved records, and subsequently of full texts, was 105 
undertaken independently by two reviewers. Data extraction was performed by a single 106 
reviewer, with all data extraction forms checked by a second reviewer. Disagreements were 107 
resolved by discussion between the two reviewers or further discussion with a third reviewer, 108 
leading to a consensus on inclusion/exclusion. 109 
 110 
Quality appraisal 111 
Quality of included studies was assessed independently by two reviewers using the Quality 112 
Assessment Tool for Diagnostic Accuracy Studies 2 [QUADAS-2; 16] which was tailored to 113 
the research as recommended. Tailoring of the QUADAS-2 tool included adding a topic-114 
specific signalling question and defining appropriate reference standards and cut-offs for 115 
participant exclusions, as well as guidance on how many positive signalling questions are 116 
required for an overall positive rating in terms of bias and applicability concerns. (See 117 
supplement 2 for signalling questions and supplement 3 for guidance notes). Disagreements 118 
were resolved by discussion between the two reviewers or through discussion with a third 119 
reviewer, leading to a consensus on study quality. 120 
 121 
Data summary and synthesis 122 
Meta-analysis was not possible due to incomplete 2x2 tables and heterogeneity in study 123 
design. Therefore, a narrative synthesis of results is provided. 124 
 125 
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Results 126 
Searching, sifting, and sorting 127 
One thousand two hundred and seventy-five unique records were identified. Seventy six were 128 
retained after sifting titles and abstracts. Assessment of full text papers against 129 
inclusion/exclusion criteria resulted in ten studies being included in our review; five studies 130 
reporting screening experiences [12, 17-20] and five retrospective case-control studies using 131 
stored samples from known TYR1 cases [14, 21-24]. All ten papers were identified through 132 
electronic database searches. Full details regarding the numbers of studies retained and 133 
excluded at each stage of the review is provided in figure 1. A list of excluded studies (with 134 
reasons) is given in supplement 4. 135 
 136 
+++ Figure 1 +++ 137 
 138 
Quality appraisal 139 
The overall risk of bias and applicability concerns of the included studies are provided in 140 
figure 2. A summary of the methodological quality for each of the included studies is given in 141 
supplement 5. Risk of bias was considered high in two or more domains in six of ten studies 142 
(60%) and in one domain in the remaining four studies (40%). No study was judged as low or 143 
unclear risk of bias in all four domains. In the patient selection domain, all five case-control 144 
studies [14, 21-24] were considered to be at a high risk of bias. One study reporting a 145 
screening experience [20] was considered to be at a high risk of bias as the study population 146 
included screening samples taken from babies that were symptomatic and/or outside the 147 
‘newborn’ period. There were significant concerns regarding applicability of the research to 148 
the UK screening population in seven studies as the incidence of TYR1 was higher than 149 
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expected in the UK population and/or screened dried blood spot samples were collected 150 
before five days or after eight days of life [14, 17-20, 22, 24].    151 
In the index test domain, five studies were judged to have a high risk of bias as the 152 
results of the reference test were known when interpreting the index test in all case-control 153 
studies and the SUAC threshold was not pre-specified [14, 21-24]. Applicability concerns 154 
were low for all ten studies.  155 
In the reference test domain, two studies were judged to be at high risk of bias as 156 
case-controls received a screening test (second-tier test measuring SUAC directly or 157 
indirectly in babies with elevated tyrosine levels) as a reference standard [23, 24]. The 158 
remainder of the studies had an unclear risk of bias as they did not report the method of 159 
diagnosis, or did not report sufficient information to allow a judgement to be made [12, 14, 160 
17-22]. Applicability concerns were high in seven studies as babies that screened negative in 161 
studies reporting screening experiences or were used as controls did not receive an 162 
appropriate reference standard, i.e. diagnostic testing or clinical follow-up for at least two 163 
years [12, 17-20, 23, 24]. 164 
In the flow and timing domain, all ten studies were considered to be at high risk of 165 
bias. The reasons for this were that the reference standards used to confirm TYR1 status for 166 
screen-positives and screen negatives (or cases and controls) were not the same, follow-up of 167 
those people who screened-negative was not defined or not conducted, and losses to follow-168 
up were not reported [12, 14, 17-24].  169 
 170 
+++ Figure 2 +++ 171 
 172 
Characteristics of included studies 173 
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Included studies are summarised in table 1 and supplement 6. There were ten studies. Five 174 
studies reported experiences of newborn screening programmes [12, 17-20]. Data were given 175 
for screening periods ranging from 16 weeks [19] to four years one month [20]; the number 176 
of analysed screening samples ranged from 61,344, which included two cases [19], to 177 
518,687, which included three cases [20]. Five papers reported on case-control studies [14, 178 
21-24] conducted over periods between one [21] and five [22] months; the number of 179 
screening samples ranged from ~1000, which included six cases [21], to 13,532, which 180 
included 11 cases [24]. 181 
 182 
Description of screening and diagnostic tests 183 
Details of the MS/MS screening methodology and diagnostic confirmation used in the 184 
included studies are provided in supplement 6. In brief, two studies used commercially 185 
available MS/MS assays [18, 23] while all others used non-kit methods with derivatisation of 186 
SUAC to its hydrazine [12, 14, 17, 19-22, 24]. MS/MS analysis of SUAC-hydrazone [12, 14, 187 
19, 20, 24] or SUAC-hydrazone butyl ester [17, 21-23] was performed; the MS/MS 188 
methodology used was not reported by Lund et al [18]. The SUAC cut-off values used in the 189 
10 studies ranged from 1.29 µmol/l [23] to 10 µmol/l [19]. No two studies used the same cut-190 
off value. 191 
A range of approaches were reported for defining the reference standard. For 192 
individuals who screened positive or were used as cases these were: clinical diagnosis [14], 193 
“pre-natal testing” [12], DNA analysis [17, 18], analysis of SUAC in urine [12, 18, 19], 194 
analysis of plasma amino acids [12, 18], “diagnostically confirmed in accordance with 195 
institutional guidelines” [23], and on the basis of “symptoms consistent with TYR1” [20]. 196 
The method of diagnosis was not reported by Dhillon and colleagues [21] and la Marca and 197 
colleagues [22]. Four studies used more than one diagnostic approach [12, 18-20]. For 198 
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individuals who screened negative, no clinical follow-up or other reference standard was 199 
reported for all five experience reports [12, 17-20]. In the five case-control studies, two 200 
conducted second-tier testing (SUAC or 5-aminolevulinic acid dehydratase [ALAD]) in DBS 201 
with elevated tyrosine levels to identify healthy controls [23, 24], while the reference 202 
standard to confirm absence of TYR1 was unclear in the other three studies [14, 21, 22].  203 
 204 
Accuracy of screening tests 205 
The methods and thresholds used for screening, and diagnostic tests varied between studies. 206 
Results were considered positive when they exceeded the threshold as set in the individual 207 
study. Table 1 shows the test accuracy data on sensitivity, specificity, positive predictive 208 
value (PPV) and negative predictive value (NPV). 209 
 210 
+++Table 1+++ 211 
 212 
Sensitivity and specificity 213 
It was not possible to calculate sensitivity and specificity for the studies reporting screening 214 
experiences due to a lack of follow-up of people who had screened negative. For the case-215 
control studies, sensitivity was estimated to be 100% in each of the five studies, which 216 
included 29 cases in total [14, 17, 21, 23, 24]. Specificity was estimated to be 100% in four 217 
studies [14, 22-24]. This included 34,403 unaffected babies in total, 18,204 of which had an 218 
inadequate reference standard. Specificity could not be calculated for the study by Dhillon et 219 
al. [21] as they did not give a precise figure for the number of controls.  220 
 221 
Positive and negative predictive value 222 
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In the studies reporting screening experiences, the PPV was 100% in four studies, with in 223 
total eight true positive cases and no false positive cases out of 856,671 people screened [17-224 
20], and 66.7% in one study, with two true positive cases and one false positive case out of 225 
~500,000 babies screened [12]. There were very wide confidence intervals due to the small 226 
number of cases. NPV could not be calculated due to a lack of follow-up of people who had 227 
screened negative. PPV and NPV could not be calculated from the case-control studies as 228 
these values are dependent on the prevalence of the disease in the population that is being 229 
tested.  230 
 231 
Discussion 232 
We examined the test accuracy of SUAC measurement in DBS using MS/MS to screen for 233 
TYR1 in newborns. Ten studies were identified which reported test accuracy data; five 234 
studies reporting screening experiences and five case-control studies. PPV in the studies 235 
reporting screening experiences ranged from 67% (two true positive cases and one false 236 
positive case out of ~500,000 babies screened) to 100% (eight true positive cases and no false 237 
positive cases out of 856,671 people screened). We were unable to calculate sensitivity, 238 
specificity, or negative predictive value in these studies due to a lack of follow-up of babies 239 
who screened negative. Case-control studies reported clear discrimination between SUAC 240 
levels of newborns with and without TYR1.  241 
No consistent test accuracy metric was available. Papers reporting screening 242 
experiences suggested that using SUAC to screen for TYR1 resulted in no false negative 243 
results, and reported test sensitivity and specificity of up to 100%. However, these 244 
conclusions were based on a lack of awareness of false negative results rather than following 245 
up babies who had screened negative. Without proper follow-up of the population who have 246 
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been tested, for an appropriate amount of time, it is not possible to know if the absence of 247 
awareness of false negatives reflects an actual absence of false negative results.  248 
While case-control studies showed no overlap in SUAC levels between newborns 249 
with and without TYR1, the cut-offs used varied between studies and were specified 250 
retrospectively, and the assessors were not blinded to the disease status, which can result in 251 
overestimation of test accuracy. The included case-control studies were also at high or 252 
unclear risk of differential verification bias as TYR1 cases and healthy controls received 253 
different reference standards, the reference standards used were not reported in sufficient 254 
detail to assess if their accuracy was comparable, or they were not reported at all. The use of 255 
multiple reference standards across participants of a single study might have resulted in an 256 
overestimation of accuracies [25]. In addition, studies evaluating diagnostic tests in a 257 
diseased population and a separate healthy control group can overestimate the diagnostic 258 
performance compared with studies that use the index test in a clinical population covering 259 
the full range of patients without knowing their disease status [25]. 260 
Our understanding of the appropriateness of screening for TYR1 using SUAC is 261 
limited by heterogeneity in study design, the methods used for SUAC determination on 262 
DBS, and the SUAC cut-off values. For example, the SUAC cut-offs used in the screening 263 
test to identify possible cases of TYR1 ranged from 1.29 µmol/ l [23] to 10 µmol/l [19]. 264 
Proficiency testing results for SUAC in dried blood spots have shown large differences 265 
among screening laboratories in SUAC recovery reflecting analytic biases, which might 266 
explain the wide variation in cut-off values of the studies in our review [26]. Differences in 267 
recovery could be explained by the method used (kit TMS vs. non-kit TMS; butyl ester 268 
derivatisation vs. non-derivatisation), DBS extraction strategy (freshly punched DBS, 269 
residual DBS or co-extraction of AA, AC, and SUAC, respectively), internal standard used 270 
(13C-SUAC, 5,7-dioxooctanoic acid, or TMS kit internal standard), or the calibration strategy 271 
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used (DBS calibrators, TMS internal standard/other liquid standard or kit internal standard 272 
only, respectively). Laboratories that measure low quantitative SUAC results usually used 273 
lower cut-off values to avoid misclassifications [26]. This highlights an important issue in 274 
how screening tests are evaluated. In this paper, we examine test accuracy, meaning the 275 
association between results from the test under investigation with the presence or absence of 276 
the target disease. However, the term ‘accuracy’ has multiple meanings. Within method 277 
validation (the process used to confirm that tests are suitable for their intended purpose), 278 
‘analytical’ accuracy refers to the degree to which test results and the true value of the 279 
measured quantity agree and how reproducible and reliable the test is [27]. The analytical 280 
performance of the used SUAC assays has been described in some of the included studies. 281 
The recovery of SUAC was assessed in five studies by assaying DBS specimens enriched 282 
with predetermined (low to high) SUAC concentrations and was reported to be 51% [23], 72-283 
80% [19], 75-78% [14], 75-86% [21], and 97-100% [22] of the expected value, respectively. 284 
The quantification limit (the lowest amount of SUAC in a sample which can be reliably 285 
quantified) was reported in four studies and was 0.4 µmol/l [22], 0.5 µmol/l [23][19] and 1 286 
µmol/l [14]. The calibration was reported to be linear up to 50 µmol/l [14], 100 µmol/l [19, 287 
22, 24], 240 µmol/l [21], and 250 µmol/l [23], respectively. Precision (the ability to 288 
consistently reproduce a result when sub-samples are taken from the same specimen) results 289 
were presented in seven studies with inter-assay coefficients of variation (CV) at different 290 
SUAC concentrations of 10.0-12.2% [14], 7.1-8.5% [21], 3.50-4.49% [22], 5.8-13% [19], 291 
15.8-16.7% [24], 17.29-19.00% [23] and 30% in a pooled sample assay [20]. Taken together, 292 
the analytical performance of the screening tests used in the included studies was in 293 
agreement with previously reported proficiency testing outcomes [26, 28, 29], showing large 294 
between-laboratory differences in SUAC recoveries (mostly incomplete recoveries) 295 
depending on the method used and reproducible within-laboratory recoveries. There is need 296 
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to harmonise quantitative results among laboratories. Despite differences among methods in 297 
SUAC recoveries (analytical bias), each method seems to have an acceptable precision and 298 
might therefore still be able (when using a cutoff value appropriate for the selected method) 299 
to reliably sort asymptomatic newborns into probable TYR1 cases and non-cases. De Jesus et 300 
al. [29] and Adam et al. [26] stress in their papers that bias in quantitative results can be 301 
tolerated if the screening test reliably sorts people into those who (probably) do have the 302 
disease of interest and those who (probably) don’t. Any differences in the test accuracy 303 
between studies might be due to the timing of the test, the SUAC assay used, the cut-off used 304 
for classifying the disease status, use of repeat testing in samples with borderline SUAC 305 
levels, or variation in normal SUAC values in the tested newborn population.  306 
 Our review has a number of limitations. First, we were unable to synthesise our 307 
findings numerically due to incomplete 2x2 tables for reporting screening experiences, and 308 
heterogeneity in study design, the MS/MS method used, and the SUAC cut-off values. 309 
Second, we restricted our search to English language papers; non-English-language papers 310 
may be available and add further information. Third, we tailored the applicability questions 311 
for the QUADAS-2 in relation to the newborn screening in the UK. For example, in the UK 312 
newborn screening takes place five to eight days after birth, so studies in which samples were 313 
taken before or after this were rated as having high concerns regarding applicability. None of 314 
the studies we identified were conducted in the UK, and the usual time at which screening 315 
takes place varies by country; in many European countries newborn screening is conducted 316 
three days after birth. Therefore, the criteria for a high applicability concern might be 317 
different outside the UK. 318 
While results from case-control studies are promising they are not definitive, as we 319 
know that case-control designs tend to overestimate test accuracy [25]. A research project 320 
using MS/MS measurement of SUAC from DBS with follow-up of screen-negatives for at 321 
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least two years would considerably strengthen the test accuracy data. This could be achieved 322 
by following up one of the existing cohorts described in this review by searching 323 
hospital/primary care databases for cases of TYR1 that were identified symptomatically. 324 
While this approach would not provide a definitive answer, it would enable a measure of 325 
false-negative cases that is currently missing from the literature. 326 
 327 
Conclusions 328 
MS/MS measurement of SUAC from DBS looks like a promising screening test for TYR1 329 
but test accuracy from proof-of-concept studies should be confirmed in screening studies that 330 
include appropriate follow-up of screen-negatives. 331 
 332 
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Figure 1. PRISMA flow diagram of records through the systematic review 393 
*See supplement 4 for list of excluded studies with reasons 394 
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Figure 2. Risk of bias and applicability concerns graph: review authors' judgements about 395 
each domain presented as percentages across included studies 396 
 397 
 398 
 399 
Table 1.  Accuracy of newborn screening tests using MS/MS measurement of SUAC 
Study No. screened SUAC  
cut-off 
2x2 table Sensitivity% 
(95%CI) 
Specificity% 
(95%CI) 
PPV%  
(95%CI) 
NPV% 
(95%CI) 
 TP TN FP FN 
Studies reporting screening experiences 
La Marca [17] 
  
136,075 [Overlap of 13,000 with 
[22]] 
2 µmol/l 2 NA 0 NA NA NA 100 
(19.8-100) 
NA 
Lund [18] 
 
140,565 2.1 U 1 NA 0 NA NA NA 100  
(5.5-100) 
NA 
Morrissey [12] 
 
~500,000 3 µmol/l 2 NA 1 NA NA NA 66.7  
(12.5-98.2) 
NA 
Sander [19] 
 
61,344 ≥ 10 µmol/l 2 
 
NA 0 NA NA NA 100  
(19.8-100) 
NA 
Zytkovicz [20] 
 
518,687: 515,592 newborns, 
3095 over 1 month old 
> 4 µM 
(recently 
reduced to 
3.3 µM) 
positive; 
SUAC  
3 NA 0 NA NA NA 100  
(31.0-100) 
NA 
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1.0-3.3 µM 
intermediate 
Case-control studies 
Allard [14] 
 
 
4,002: 3 cases, 3,199 controls  2 µmol/l 3 3199 0 0 100  
(31.0-100) 
100 
 (99.85-100) 
 N/A N/A 
Dhillon [21] 
 
>1,026: 6 cases, >1,000 controls 3 µmol/l 6 >1,000 0 0 100 
 (51.7-100) 
N/A N/A N/A 
La Marca [22] 
 
13,006: 6 cases, 13,000 controls 
[Overlap with la Marca [17]]  
2.4 µmol/l 6 13,000 0 0 100  
(51.7-100)  
100 
 (99.96-100)  
N/A N/A 
Metz [23] 
 
4686: 3 cases, 4683 controls 1.29 µmol/l 3 4683 0 0 100 
(30.9-100) 
100 
(99.90 – 100) 
N/A N/A 
Turgeon [24] 
 
13,532: 11 cases, 13,521 
controls. 
> 5 µmol/l 11 13,521 0 0 100  
(67.9-100) 
100 
 (99.96-100) 
N/A N/A 
CI, confidence interval; FN, false negative; FP, false positive; NA, not applicable; NPV, negative predictive value; PPV, positive predictive value; SUAC, succinylacetone; TN, true negative; 
TP, true positive 
Numbers in italics were calculated by reviewers. 
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Supplement 1. Search strategy for Ovid Medline (26th January 2016). 
# Search Results 
1 exp Tyrosinemias/ 309 
2 (tyrosinemia* or tyrosinaemia*).mp. [mp=title, abstract, original title, name 
of substance word, subject heading word, keyword heading word, protocol 
supplementary concept word, rare disease supplementary concept word, 
unique identifier] 
989 
3 (tyr1 or tyr-1).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
961 
4 (tyri or tyr-i).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
28 
5 (((fumarylacetoacetate adj hydrolase) or fumarylacetoacetase or fah) adj2 
deficien*).mp. [mp=title, abstract, original title, name of substance word, 
subject heading word, keyword heading word, protocol supplementary 
concept word, rare disease supplementary concept word, unique identifier] 
122 
6 metabolism, inborn errors/ or exp amino acid metabolism, inborn errors/ or 
exp amino acid transport disorders, inborn/ 
32709 
7 inborn metabolic disorder*.mp. 70 
8 inborn metabolic error*.mp. 71 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 34016 
10 suac.mp. 23 
11 exp Heptanoates/ or succinylacetone.mp. 425 
12 succinylacetoacetate.mp. 13 
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13 51568 18 4 succinylacetone.rn. 218 
14 4,6-dioxoheptanoate.mp. 4 
15 exp Heptanoic Acids/ or 4,6-Dioxoheptanoic acid.mp. 6027 
16 10 or 11 or 12 or 13 or 14 or 15 6145 
17 tandem mass spectrometry.mp. or exp Mass Spectrometry/ or exp Tandem 
Mass Spectrometry/ 
194658 
18 mass spectro*.mp. 216542 
19 tms.mp. 7402 
20 17 or 18 or 19 243854 
21 exp Dried Blood Spot Testing/ or (Blood spot* or dry blood spot* or dried 
blood spot*).mp. 
3297 
22 dbs.mp. 5020 
23 21 or 22 7449 
24 neonatal screening.mp. or exp Neonatal Screening/ 8921 
25 neonat* screening.mp. 8930 
26 newborn screening.mp. 3462 
27 ((newborn* or neonat*) adj5 screen*).mp. [mp=title, abstract, original title, 
name of substance word, subject heading word, keyword heading word, 
protocol supplementary concept word, rare disease supplementary concept 
word, unique identifier] 
12346 
28 24 or 25 or 26 or 27 12346 
29 20 and 28 821 
30 16 or 29 or 23 14082 
31 9 and 30 729 
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Supplement 2. QUADAS-2 checklist 
QUADAS-2 (adjusted) 
First author surname and year of publication:  
Name of first reviewer: Name of second reviewer: 
Phase 1: State the review question: 
2) What is the test accuracy (sensitivity, specificity, and predictive values applicable to UK prevalence) 
of SUAC measurement in dried blood spots using TMS for TYR1 screening? 
Patients (setting, intended use of index test, presentation, prior testing):  
Index test(s):  
Reference standard and target condition:  
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Phase 2: Draw a flow diagram for the primary study 
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Phase 3: Risk of bias and applicability judgments 
QUADAS-2 is structured so that 4 key domains are each rated in terms of the risk of bias 
and the concern regarding applicability to the research question (as defined above). Each 
key domain has a set of signalling questions to help reach the judgments regarding bias and 
applicability. 
DOMAIN 1: PATIENT SELECTION 
A. Risk of Bias  
Describe methods of patient selection: 
+ Was a consecutive or random sample of patients enrolled? Yes/No/Unclear 
+ Was a case-control design avoided? Yes/No/Unclear 
+ Did the study avoid inappropriate exclusions? Yes/No/Unclear 
+ Were screening samples taken in asymptomatic babies? Yes/No/Unclear 
Could the selection of patients have introduced bias? RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Describe included patients (prior testing, presentation, intended use of index test and setting): 
 
Is there concern that the included patients do not match the 
review question? 
 
CONCERN: LOW/HIGH/UNCLEAR 
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DOMAIN 2: INDEX TEST(S) 
If more than one index test was used, please complete for each test. 
A. Risk of Bias  
Describe the index test and how it was conducted and interpreted: 
+ Were the index test results interpreted without knowledge    
   of the results of the reference standard? 
Yes/No/Unclear 
+ If a threshold was used, was it pre-specified? Yes/No/Unclear 
Could the conduct or interpretation of the index test have 
introduced bias? 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Is there concern that the index test, its conduct, or 
interpretation differ from the review question? 
 
CONCERN: LOW/HIGH/UNCLEAR 
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DOMAIN 3: REFERENCE STANDARD 
A. Risk of Bias 
Describe the reference standard and how it was conducted and interpreted: 
 
+ Is the reference standard likely to correctly classify the  
   target condition? 
Yes/No/Unclear 
+ Were the reference standard results interpreted without  
   knowledge of the results of the index test? 
Yes/No/Unclear 
Could the reference standard, its conduct, or its interpretation 
have introduced bias? 
RISK: LOW/HIGH/UNCLEAR 
B. Concerns regarding applicability 
Is there concern that the target condition as defined by the 
reference standard does not match the review question? 
 
CONCERN: LOW/HIGH/UNCLEAR 
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DOMAIN 4: FLOW AND TIMING 
A. Risk of Bias 
Describe any patients who did not receive the index test(s) and/or reference standard or who were excluded 
from the 2x2 table (refer to flow diagram): 
 
 
Describe the time interval and any intervention between index tests(s) and reference standard: 
+ Was there an appropriate interval between index test(s) 
and reference standard? 
Yes/No/Unclear 
+ Did all patients receive a reference standard? Yes/No/Unclear 
+ Did all patients receive the same reference standard? Yes/No/Unclear 
+ Were all patients included in the analysis? Yes/No/Unclear 
Could the patient flow have introduced bias? RISK: LOW/HIGH/UNCLEAR 
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Supplement 3. Modified QUADAS-2 and guidance notes for tyrosinaemia type 1 screening 
 
Domain 1: Patient selection 
SUAC levels in symptomatic older children might be different to levels in asymptomatic 
patients in the newborn period [14, 20]. Therefore choice of patient population in terms of 
disease status is an important factor for consideration for bias and applicability. 
 
A. Risk of bias 
Guidance: 
Was a consecutive or random sample of patients enrolled? 
This question should only be answered with ‘yes’ if the study clearly states that newborn babies 
(rather than samples) were recruited consecutively or randomly.  
 
Was a case-control design avoided? 
We would at least expect a prospective cohort design. Therefore, if the study is a case-control 
study this question should be answered with ‘No’.  
 
Did the study avoid inappropriate exclusions?  
If the study excludes >10% of participants with or without specifying reasons, the exclusions 
should be considered as inappropriate. This cut-off has been determined pragmatically. If 
studies reporting experiences of implementing screening have a reported screening uptake of 
at least 95% this question can be answered with ‘yes’.  
 
Were screening samples taken in asymptomatic babies? 
This question can be answered with ‘yes’ if all samples were taken in babies without clinical 
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symptoms of TYR I. The question should be answered with ‘no’ if symptomatic children 
were tested and the risk of bias classed as ‘high’. 
 
B. Concerns regarding applicability 
Guidance:  
The timing of sample collection might influence test performance. As the research question 
aims to address screening of newborns within NHS schedules of 5-8 days, sampling outside 
this window, e.g. at 3 days (many European countries including Ireland, Italy, Denmark) 
might not produce outcomes applicable to the NHS context. Likewise, a cohort study in a 
country with significantly different prevalence of cases will affect applicability.  
 
Applicability concerns should be regarded ‘high’ if >10% of blood spot specimens were 
collected in babies >10 days or < 5 days. 
 
Applicability concerns should be also considered ‘high’ if TYR1 prevalence in cohort studies 
differs significantly from that expected in UK newborns (~1:100,000) , i.e. in countries: 
Québec province of Canada, parts of Finland and Norway, Pakistan, Middle East and North 
Africa [7, 10, 30, 31]. 
 
Domain 2: Index test 
The main sources of bias introduced by conducting and interpreting the index test are 
blinding and defining the threshold. If the reference standard is carried out before the index 
test (e.g. in case control studies) it is important to blind personnel to the results of the 
reference standard. 
 
Tyrosinemia type 1 screening test accuracy 
34 
 
The QUADAS-2 tool requires a threshold to be pre-specified in the methods in order to avoid 
adjustment of the threshold according to the test outcome.  
 
A. Risk of bias 
Were the index test results interpreted without knowledge of the results of the reference 
standard? 
In case-control design studies blinding needs to be specifically mentioned for this question to 
be answered with ‘yes’.  
 
Was a threshold explicitly pre-specified? 
For this question to be answered with ‘yes’ the study needs to mention what kind of threshold 
was to be used (e.g. SUAC ≥2.0 µmol/l) and clearly state that it was specified before the start 
of the study. If the study reports adjustment to the threshold and reports results according to 
adjusted thresholds this question should be answered with ‘no’.  
 
B. Concerns about applicability 
If the study uses different screening tests to TMS measurement of SUAC as primary marker 
(i.e. SUAC as 2nd-tier test) concerns regarding the applicability of the study should be classed 
as ‘high’.  
 
Domain 3: Reference standard 
The most useful test for diagnosis of TYR1 is measurement of SUAC in plasma, dried blood 
spot or urine by a specific assay, which is highly specific and sensitive. SUAC may not be 
detected in routine organic analyses in urine, particularly if the concentration of SUAC is 
very low or the urine is very dilute. Molecular genetic testing for common FAH pathogenic 
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variants or detection of decreased activity of the FAH enzyme in liver tissue or cultured 
fibroblasts might also be used for diagnosis (http://www.ncbi.nlm.nih.gov/books/NBK1515) 
but is generally used to support SUAC testing and is unlikely used as the initial test of 
investigation because it is still expensive and deletions are not always. 
 
Plasma amino acids can only be seen as supportive of a diagnosis as they are very 
nonspecific.  
 
Follow-up as a reference standard should be for at least two years to confirm absence of 
TYR1 [9]. 
 
Furthermore, blinding is an issue in studies reporting experiences as only samples with high 
SUAC samples will be referred to further testing. If the index test is carried out before the 
reference standard, blinding to the results of the index tests is important. 
 
A. Risk of bias 
Is the reference standard likely to correctly classify the target condition? 
For studies that used SUAC levels in urine, molecular genetic testing or at least 2 year 
follow-up as reference standard on their own or in combination this question should be 
answered with ‘yes’. If studies only used plasma amino acids (Tyr) levels as a reference 
standard the question should be answered with ‘no’. If studies using SUAC in urine as the 
reference standard do not define the SUAC threshold used the question should be answered 
with ‘unclear’. 
 
Were the reference standard results interpreted without knowledge of the results of the index 
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test? 
This question should be answered with ‘no’ if the study reports an experience report. In case-
control studies blinding of the index test results is not an issue and can therefore be classed as 
‘yes’. In cohort studies blinding should be specifically mentioned for the question to be 
answered with ‘yes’. 
 
B. Concerns about applicability 
The concern of applicability of the reference standard will be ‘low’ if SUAC levels in urine, 
molecular genetic testing or at least 2 year follow-up were the predefined reference standard 
in the studies assuming that they all identify TYR1 and no other type of tyrosinaemia. 
 
Domain 4: Flow and Timing 
Innate residual FAH activity as well as protein (especially phenylalanine) intake have been 
shown to influence production of SUAC in TYR1 cases [20]. SUAC usually accumulates 
over time in effected cases and late testing is therefore associated with better test 
performance. On the other hand there are also reports that SUAC concentrations in 
asymptomatic newborns were higher than in symptomatic older infants when hepatic and 
renal dysfunction has set in [20]. Since TYR1 is a progressive condition, the time interval 
between the index test and reference standard is of importance. Partial and differential 
verification bias are a concern in studies where screen-negative children are not referred for 
further testing and receive no reference standard (experience reports) or are followed up for a 
certain time period only (cohort studies) as these studies have limited data on false negatives. 
 
Children with negative index test result should be followed up for at least two years to 
confirm absence of TYR1 [9]and losses to follow-up should be reported. 
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A. Risk of bias 
Was there an appropriate interval between index test(s) and reference standard? 
This question can be answered with ‘yes’ if the reference standard is SUAC in urine and the 
time interval is <10 days. This number has been chosen arbitrarily on the basis that small 
molecules have been shown to increase from undetectable to detectable levels between birth 
and two to four days of life. It is very likely that bias will exist if the index test and reference 
standard (both measuring SUAC) are not undertaken at the same time. However, no evidence 
was identified to base this cut-off on. The question should be answered with ‘no’ if treatment 
commenced between index test and references standard that decreases the level of SUAC and 
bias should be regarded as ‘high’. The question can be answered with ‘yes’ if molecular 
testing or follow-up were used as the reference standard.  
 
Did all patients receive a reference standard? 
This question can be answered with ‘yes’ if all participants are recruited on the basis of the 
above mentioned reference standard results (case-control studies). In prospective cohort 
studies, this question can be answered with ‘yes’ if all those who screen positive have 
received one of the above mentioned reference standards and those who screened negative 
were followed up for at least two years and losses to follow-up are reported and are <10%. 
 
The question should be answered with ‘unclear’ if the study provides no information on how 
healthy controls were identified in case-control studies and risk of bias should be classed as 
‘high’.  
 
Risk of bias should be considered as ‘high’ in case-control studies which included healthy 
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controls identified on the basis of newborn screening results (e.g. two tier screening of Tyr 
levels followed by SUAC in dried blood spots) and/or follow-up for less than two years; or in 
prospective cohort studies which followed up screen negatives for less than two years. 
 
Risk of bias should be considered as ‘high’ in studies that did not specify and describe 
(including threshold for SUAC levels in urine) the reference standard. 
 
Did all patients receive the same reference standard? 
This question should be answered with ‘no’ if patients received different reference standards 
or if positive cases received a different reference standard to negative subjects. This question 
should also be answered with ‘no’ if a list of reference standards is given but no report is 
made of which patients received which reference standard(s). If this question is answered 
with ‘no’, the risk of bias should be regarded as ‘high’ as the different reference standards 
cannot be classed as equivalent.  
 
Were all patients included in the analysis? 
If inconclusive or intermediate results are not considered in the analysis the question should 
be answered with ‘no’. If patients lost to follow-up were not included in the analysis or >50% 
of patients were lost to follow (even if considered in the analysis) the question should be 
answered with ‘no’. (The actual proportion of patients lost to follow-up needs to be recorded 
for each study). If studies report a clinical experience and base test accuracy estimates on 
interim results and not all patients were followed up the question should be answered with 
‘no’. In all three cases the risk of bias should be classed as ‘high’. 
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Supplement 4. Excluded studies (n=66) 
Reference Reason for exclusion 
Abdel-Hamid M. Tisocki K. Sharaf L. Ramadan D. 
2007. Development, validation and application 
of tandem mass spectrometry for screening of 
inborn metabolic disorders in Kuwaiti infants. 
Medical Principles & Practice 16: 215-221. 
Not SUAC as primary marker 
Arn PH. 2007. Newborn screening: current status. 
Health Affairs 26: 559-566. 
No test accuracy data 
Bennett MJ. 2013. "The expansion of biomarker 
measurement for metabolic disease diagnosis." 
Annals of Clinical Biochemistry 50: 386-387. 
No test  accuracy data for TYR1 
screening 
Bodamer, O. A., et al. 2007. Expanded newborn 
screening in Europe 2007. Journal of Inherited 
Metabolic Disease 30: 439-444. 
No test  accuracy data 
Bodamer OA. Muhl A. 2005. Analysis of acylcarnitine 
ester for neonatal screening of inborn errors of 
metabolism using tandem mass-spectrometry. 
Monatshefte Fur Chemie 1368: 1293-1297. 
Not TYR1 screening using 
SUAC as primary marker 
Bulbul S. 2014. Novel approach for Newborn Errors in 
Metabolism Screening (NEMS) by NMR: 
Clinical NEMS-by-NMR Study in Turkey. 
Clinical Biochemistry 47: 700-701. 
NMR analysis of urine samples 
Chace DH, Hannon WH. 2010. Impact of second-tier Editorial 
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testing on the effectiveness of newborn 
screening. Clinical Chemistry 56: 1653-1655. 
Champion MP. 2010. An approach to the diagnosis of 
inherited metabolic disease. Archives of Disease 
in Childhood Education & Practice 95: 40-46. 
No test  accuracy data 
Couce ML. Castiñeiras DE. Bóveda MD. Baña A. 
Cocho JA. Iglesias AJ. Colón C. Alonso-
Fernández JR. Fraga JM. 2011. Evaluation and 
long-term follow-up of infants with inborn errors 
of metabolism identified in an expanded 
screening programme. Molecular Genetics & 
Metabolism 104: 470-475. 
Tyrosine as primary screening 
marker 
Denes J. Szabó E. Robinette SL. Szatmári I. Szőnyi L. 
Kreuder JG. Rauterberg EW. Takáts Z. 2012. 
Metabonomics of newborn screening dried 
blood spot samples: a novel approach in the 
screening and diagnostics of inborn errors of 
metabolism. Analytical Chemistry 84: 10113-
10120. 
No test  accuracy data for TYR1 
screening 
Eddy M. Gottesman GS. 2009. Newborn metabolic 
screening and related pitfalls. Missouri Medicine 
106: 234-240. 
No test  accuracy data for TYR1 
screening 
Fernhoff P. M. 2009. Newborn screening for genetic 
disorders. Pediatric Clinics of North America 
56: 505-513. 
No test  accuracy data for TYR1 
screening 
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Feuchtbaum L. Dowray S, Lorey F. 2010. The context 
and approach for the California newborn 
screening short- and long-term follow-up data 
system: Preliminary findings. Genetics in 
Medicine 12: S242-S250. 
No test  accuracy data for TYR1 
screening 
Fingerhut R. Olgemoller B. 2009. Newborn screening 
for inborn errors of metabolism and 
endocrinopathies: an update. Analytical & 
Bioanalytical Chemistry 393: 1481-1497. 
No test  accuracy data for TYR1 
screening 
Frazier DM. Millington DS. McCandless SE. Koeberl 
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Supplement 6. Study characteristics and MS/MS screening methodology for Tyrosinemia type 1 
Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
Allard [14] 
 
USA (Canada) 
 
New England 
Newborn Screening 
Programme 
 
Time period NR 
Case-control 
study: 
Stored original 
newborn DBS 
specimens of 3 
known TYR1 
cases and 3,199 
DBS of 
unaffected 
newborns 
Original 
newborn 
screening filter 
paper cards  
Controls: 
stored for up 
to 5 days at 
RT; 
Cases: stored 
at 
-20°C for 4-22 
months. 
3.2 mm (1/8 
inch) diameter 
filter paper 
disc punch 
Controls: 
median 1.9 
days; 
Cases: 
median 
2 days, range  
1-3 days. 
No Extraction of SUAC 
from residual DBS 
(already extracted 
with methanol for 
AA and AC 
analysis) with 
acetonitrile: water 
(80:20 by volume) 
containing 0.1% 
formic acid, 15 
mmol/l hydrazine 
hydrate (0.1% by 
volume), and 100 
nmol/l DOA as 
internal standard. 
Separate MS/MS 
analysis of SUAC- 
hydrazone 
Quattro LC triple-
quadrupole tandem 
mass spectrometer 
(Micromass Inc, 
USA)/ 
Positive ion mode;  
Cone energy 20 V; 
Collision energy 
11eV. 
SRM mode: 
SUAC-hydrazone 
m/z 155.1 → 137.1; 
DOA  
m/z 169.1 → 151.1. 
Normal range 
SUAC  
< 2 µmol/l 
(study-derived) 
/ 
23.2 - 46.7 
µmol/l 
NR /  
Clinically 
diagnosed 
cases, NR for 
controls 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
Dhillon 
[21] 
 
 
 
California/ 
USA 
 
California Newborn 
Blood Spot Screening 
Programme 
 
1 month 
Case-control 
study: 
>1,000 NBS 
specimens 
identified as 
normal and 
stored NBS 
specimens of 6 
confirmed TYR1 
cases 
 
3.2 mm DBS 
punch 
NR (newborn 
screening 
programme) 
No Simultaneous 
extraction of AA, 
AC, and SUAC 
from DBS using 
acetonitrile:water 
(8:2 by volume) 
containing 0.05% 
formic acid, 3.0 
mmol/l hydrazine 
hydrate and 
13C5-SUAC as 
internal standard. 
Derivatisation of 
AA, AC and 
SUAC-hydrazone 
using butanolic-
HCl. 
LC-MS/MS 
analysis of butyl 
esters in a single 
run 
Triple quadrupole 
tandem mass 
spectrometer, 
Micromass Quattro 
Micro (Waters 
Corporation) / 
Positive ion mode; 
Capillary voltage 3.2 
kV; 
Multiple reaction 
monitoring; 
Butyl ester of 
SUAC-hydrazone: 
m/z 211.20 → 
137.15; 
Butyl ester of 
13C5-SUAC 
hydrazone 
m/z 216.20 → 
142.15 
Cut-off  
SUAC 3 
µmol/l 
(study-derived) 
/  
6.81 - 24.37 
µmol/l 
NR / NR 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
La Marca 
[22] 
 
 
Italy 
 
January 2007 to May 
2007 
13,000 newborn 
screening spots 
from healthy 
controls and 10 
stored DBS 
samples from 6 
confirmed TYR1 
cases 
DBS using 
heel stick, 
spotted on 
filter paper 
(903, 
Whatman), 
3.2 mm punch 
(3.4 µl blood) 
used 
Controls: 48-
72 h of life; 
Cases: 
3 days-11 
months 
No Simultaneous 
extraction of AA, 
AC and SUAC: 
Addition of DOA 
(or 13C2-SUAC) as 
internal standard to 
the methanolic 
solution of 
deuterated AC and 
AA; 
Extraction and 
derivatisation of 
SUAC in a single 
step using 3 mmol/l 
hydrazine in 
water/methanol 
(50:50); 
Butylation; 
Simultaneous 
MS/MS 
measurement of 
AC, AA and 
SUAC- hydrazone 
as butyl esters 
Applied 
Biosystems/MDS 
Sciex API 4000TM 
triple-quadrupole 
MS equipped with a 
TurboV-Spray® 
source with turbo 
gas temperature set 
at 425ºC / 
Positive ionisation 
polarity +5500 V. 
Multiple reaction 
monitoring: 
Butyl ester of 
SUAC-hydrazone 
m/z 211 → 137; 
Internal standards 
Butyl ester of  
13C2-SUAC-
hydrazone 
m/z 219 → 139; 
Butyl ester of DOA 
m/z 225 → 151. 
Declustering enery 
55V; 
Collision energy 
19eV 
SUAC 
Normal range 
< 2.4 µmol/l 
(median+5SD) 
/ 3.3 - 18.3 
µmol/l 
NR / NR 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
La Marca 
[17] 
 
Tuscany/ 
Italy 
 
January 2007-2010 
136,075 
screened in 
Tuscan 
expanded 
newborn 
screening 
programme; 
Overlap of 
13,000 samples 
reported by La 
Marca [22] 
DBS NR 
[48-72 h of 
life, from La 
Marca [22]] 
No NR 
(see La Marca [22]) 
NR 
See la Marca [22]  
SUAC 
Normal value < 
2 µmol/l /  
7.6 - 14.1 
µmol/l 
NR / 
Detection of 
SUAC in urine 
and plasma for 
screen-
positives; NR 
for screen-
negatives 
Lund  
[18] 
 
Denmark, Faroe 
Islands, Greenland 
 
Routine expanded 
newborn screening 
programme 
 
February 2009 to 
March 2011 (26 
months) 
Prospective 
routine 
expanded 
newborn 
screening in 
140,565 
newborns 
DBS using 
heel prick, 
spotted om 
filter paper 
(Schleich and 
Schuell 903 
filter paper 
until 2010, 
then gradually 
replaced by the 
Ahlstrom 226) 
 
2-3 days; 
Median 2.5 
days. 
Preterm 
newborns: 
repeated test 
at gestational 
age 32 weeks 
or when oral 
feeding had 
been 
established 
No PerkinElmer 
Neobase non-
derivatized MS/MS 
kitTM (3040-0010) 
Waters Micromass 
Quattro micro™ 
tandem mass 
spectrometer / NR 
SUAC > 2.1 U 
/ NR 
Flagged DBS 
samples re-
analysed in 
duplicates. If 
the abnormal 
profiles were 
reproduced, 
referral to 
Center for 
Inherited 
Metabolic 
Disorders, 
Copenhagen 
University 
Hospital / 
Urine organic 
acids, plasma 
amino acids, 
molecular 
genetic analyses 
for screen-
positives; NR 
for screen-
negatives 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
Metz  
[23] 
Austria 
 
Austrian Newborn 
Screening 
Programme 1 month 
Case-control 
study: 
Prospective 
routine newborn 
screening in 
4,683 
consecutive 
newborns as 
healthy controls 
and stored DBS 
samples from 3 
confirmed TYR1 
cases 
DBS 
(Ahlstrom 226 
Paper, ID 
Biological, 
SC), one 3.2 
mm punch 
NR No MassChrom® 
Amino Acids and 
Acylcarnitines from 
Dried Blood; 
Chromsystems, 
Munich/Germany: 
Separate SUAC 
extraction 
(including 13C5-
SUAC as internal 
standard) from 
residual DBS after 
extraction of AA 
and AC; 
Derivatisation 
solution with 
~0.0005% 
hydrazine derived 
reagent;  
Transfer of SUAC-
hydrazone to AA 
and AC residues; 
Butylation; 
Simultaneous 
MS/MS 
measurement of 
AC, AA and 
SUAC- hydrazone 
as butyl esters 
FIA-MS/MS 
analyses on a 
certified TQ-
Detector MS system 
for newborn 
screening (Waters, 
Milford, MA, USA) 
/ 
Positive ion mode 
using a dwell time of 
0.05 s. 
Butyl ester of  
SUAC-hydrazone 
m/z 211 → 109. 
Butyl ester of  
13C5-SUAC-
hydrazone 
m/z 216 → 114. 
Cone (V): 20 
Collision (eV): 24 
 
SUAC 
Preliminary 
cut-off  
1.29 µmol/l; 
Derived from 
first 4,000 
specimens of 
unaffected 
newborns born 
after 32 weeks 
of gestation 
and samples 
not obtained 
within 36 h 
after birth / 
1.50 - 6.49 
µmol/l 
DBSs from 
potentially 
affected 
newborns were 
re-tested at least 
in duplicates 
from 2 separate 
blood spots 
from the same 
DBS card 
 
In case of 
positivity, 
diagnostically 
confirmed in 
accordance with 
institutional 
guidelines. 
Unaffected 
newborns 
identified by 2nd 
tier screening 
using ALAD 
when tyrosine > 
255 µmol/l 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
Morrissey  
[12] 
 
New York State/ 
USA 
 
December 2007-? 
(2008 and 2009, over 
24 months) 
~500,000 
newborns 
screened 
prospectively in 
New York State 
newborn 
screening 
programme 
DBS, 3.2 mm 
punch from a 
Guthrie card 
(~3.1µl blood) 
NR No Extraction of SUAC 
from residual DBS 
(after methanol 
extraction of AA 
and AC) after 
overnight drying 
using 
acetonitrile:water 
(80:20, containing 
0.1% formic acid, 
0.1% hydrazine, 
plus 13C5-SUAC as 
internal standard), 
MS/MS analysis of 
SUAC hydrazone 
one day after 
AA/AC analysis 
Two Waters Corp 
Micro LC MS/MS 
(Manchester, UK) 
with Hewlett-
Packard/Agilent 
 
Technologies series 
1100 HPLC pumps. 
TQD MS/MS and 
Acquity UPLC 
system (Waters 
Corp) for handling 
overload and 
maintenance / 
Selected ion 
monitoring:  
SUAC-hydrazone 
155.1 → 137.1;  
13C5-SUAC-
hydrazone 
160.1 → 142.1 
SUAC  
≥ 3.00 µmol/l 
for retest; 
Average (initial 
and retest)  
3.00-5.00 
µmol/l:  
repeat DBS 
specimen 
requested; 
Average (initial 
and retest) ≥ 
5.00 µmol/l: 
Immediate 
referral /  
18.29 - 19.65 
µmol/l 
Initial SUAC ≥ 
3.00 µmol/l 
retested in 
duplicate.  
Average (initial 
and retest) 
SUAC 3.00-
5.00 µmol/l, 
repeat DBS 
request 
 
Average SUAC 
≥ 5.00 µmol/l 
immediate 
referral to the 
appropriate 
specialty care 
center./ 
Prenatal testing 
or plasma AA 
and SUAC with 
or without urine 
organic acids 
and liver 
function for 
screenpositives. 
NR for screen-
negatives 
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Study Country, time 
period 
Study design Source and 
type of 
material 
Age at 
specimen 
collection 
Samples 
pooled? 
Method of 
extraction & 
derivatisation 
Type of MS/MS 
conditions 
Analyte and 
cut-off /  
Levels of 
SUAC in 
affected 
individuals 
Re-testing of 
positive 
screening 
samples / 
Diagnostic 
confirmation 
Sander  
[19] 
 
Germany 
 
16 weeks 
Prospective 
newborn 
screening study 
in 61,344 
unselected 
newborn 
DBS on S&S 
903 filter 
paper (3.2 
mm) 
36 – 72 hours 
after birth 
No Extraction of SUAC 
from residual DBS 
(already extracted 
with absolute 
methanol for AC 
and AA analysis) 
using acetonitrile-
water (80:20 by 
volume) containing 
formic acid, 15 
mmol/l hydrazine 
hydrate, and 
unlabelled DOA as 
internal standard. 
MS/MS analysis of 
SUAC hydrazone in 
a separate run 
MS/MS micro™ and 
Quatro LC™; 
Waters/Micromass 
Inc. / Positive ion 
mode, cone energy 
20 V, collision 
voltage 10 eV,  
dwell time at 9.1 s; 
Multiple-reaction 
monitoring mode; 
SUAC-hydrazone 
m/z 155.2 → 137.1 
and m/z 155.2 → 
109.1;  
DOA 
m/z 169.3 → 151.2 
SUAC > 10 
µmol/l /  
152 - 271 
µmol/l 
NR /  
Urinary SUAC 
and phenolic 
acids or 
tyrosine 
metabolites for 
screen-
positives. NR 
for screen-
negatives 
Tyrosinemia type 1 screening test accuracy 
59 
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Turgeon  
[24] 
Minnesota/ 
USA 
 
Mayo Clinic’s 
supplemental 
newborn screening 
programme 
 
Time period NR 
 
Case-control 
study: 13,521 
stored random 
newborn 
screening 
samples not 
suggestive of 
TYR1, based on 
2nd-tier 
screening  and 
11 stored 
original DBS 
from confirmed 
TYR1 
 
 
DBS NR No Parallel extraction 
of SUAC from 
residual DBS 
(already extracted 
with methanol for 
AA and AC 
analysis) using 
acetonitrile/ 
water/formic acid 
solution (80:20:0.1, 
v/v/v) containing 
0.1% hydrazine 
monohydrate (15 
mmol/l) and 13C5-
SUAC as internal 
standard. 
Combined MS/MS 
analysis of AC and 
AA butyl esters, 
SUAC hydrazone 
and 13C5-SUAC 
hydrazone 
Triple-quadrupole 
MS/MS (Applied 
Biosystems/MDS 
Sciex API 3000) / 
Positive ion mode 
(source voltage, 
5500 V) 
 
Method optimisation 
for detection of 
SUAC by SRM: 
SUAC-hydrazone 
m/z 155.0 → 137.0; 
13C5-SUAC-
hydrazone 
m/z 160.0 → 142.0 
SUAC > 5.0 
µmol/l /  
13 - 81 µmol/l 
NR /  
NR for cases,  
2nd-tier 
screening 
approach  for 
controls 
Tyrosinemia type 1 screening test accuracy 
60 
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Zytkovicz  
[20] 
Massachusetts/USA 
 
New England 
Newborn Screening 
Programme 
 
1 June 2008 to 30 
June 2012  
(4 years 1 month) 
518,687 samples 
received in New 
England 
newborn 
screening 
programme 
(491,472 
[94.8%] born 
nationally; 
27,215 [5.2%] 
born 
internationally) 
DBS  
(1/8 inch 
punch) 
99.4% 
newborn 
period (less 
than 1 
month); 
0.6% over 1 
month of age 
Yes  
(up to 8 
samples 
pooled) 
Pooled sample 
assay: 
SUAC from 
residual DBS 
(previously 
extracted with 
methanol for AA 
and AC) was 
extracted using 
acetonitrile: water: 
formic acid 
(80:20:0.1%) 
containing 17.7 mM 
hydrazine and 0.4 
µM 13C5-SUAC as 
internal standard. 
Up to 8 sample 
extracts pooled; 
MS/MS analysis of 
SUAC hydrazone 
 
Quantitative assay: 
Untreated (newly 
punched) DBS were 
extracted and 
analysed as above 
but not pooled 
Waters Quattro 
micro MS/MS / 
SUAC-hydrazone 
m/z 155.2 → 137.1 
and 
m/z 155.2 → 109.1; 
13C5-SUAC-
hydrazone 
m/z 160.2 → 142.1 
and 
m/z 160.2 → 114.1 
 
Pooled assay:  
SUAC > 0.55 
µM re-analysed 
individually /  
1.1 - 3.9 µM 
 
Quantitative 
assay: 
 SUAC  
> 4 µM 
(recently 
reduced to 3.3 
µM) positive; 
SUAC  
1.0-3.3 µM 
intermediate 
/  
4.9 - 23.1 µM 
Pooled assay:  
SUAC > 0.55 
µM re-analysed 
individually 
 
Quantitative 
assay:  
Samples with 
SUAC 1.0-3.3 
µM → repeat 
DBS specimen. 
SUAC > 4 µM 
(recently 
reduced to 3.3 
µM) → 
diagnostic 
testing 
recommended / 
NR (1 case had 
symptoms 
consistent with 
TYR1) for 
screen-
positives. NR 
for screen-
negatives 
 
 
 
 
 
 
 
 
AA, amino acids; AC, acylcarnitines; ALAD, 5- aminolevulinic acid dehydratase; DBS, dried blood spot; DNA, deoxyribonucleic acid; DOA, 5,7-dioxooctanoic acid; FIA, flow injection 
analysis; IEM, inborn errors of metabolism; LC, liquid chromatography; m/z; mass-to-charge ratio; NBS, newborn blood spot screening; NR, not reported; SUAC, succinylacetone; SRM, 
selected reaction monitoring; TMS, tandem mass spectrometry or tandem mass spectrometer; TYR1, Tyrosinaemia type 1 
